GlassScriptPhysician profile
Cengiz Satir
NPI 1992807713
$1,793.37
in general payments reported to CMS, 2019-2025
28 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $41.40 · 2021: $251 · 2022: $452 · 2023: $327 · 2024: $387 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $362.81 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $227.89 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $220.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $87.92 | 2019-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $71.56 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $67.55 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.36 | 2019-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $61.89 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $60.58 | 2022-2023 | Epkinly |
| Dexcom, INC. | $59.41 | 2023-2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $54.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $53.35 | 2024 | Farxiga, Breztri |
| Pfizer INC. | $51.12 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $37.75 | 2023-2024 | Keveyis |
| Abbott Laboratories | $37.58 | 2021-2024 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $37.42 | 2021 | |
| Corium, LLC | $34.17 | 2024 | Azstarys |
| Almatica Pharma LLC | $27.53 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.40 | 2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $23.64 | 2022 | |
| Nevro Corp. | $20.91 | 2022 | |
| Hologic Sales and Service, LLC | $20.71 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $17.61 | 2025 | Neffy |
| Halozyme INC | $15.19 | 2023 | |
| Pharming Healthcare, INC. | $14.68 | 2023 | Ruconest |
| Arbor Pharmaceuticals, INC. | $14.11 | 2022 | |
| Exact Sciences Corporation | $14.07 | 2025 | The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cengiz Satir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.